Pharvaris (NASDAQ:PHVS) Sees Large Growth in Short Interest

Pharvaris (NASDAQ:PHVS) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 487,300 shares, an increase of 24.7% from the February 13th total of 390,900 shares. Currently, 2.8% of the company’s stock are short sold. Based on an average trading volume of 55,500 shares, the short-interest ratio is presently 8.8 days.

Analyst Upgrades and Downgrades

Separately, JMP Securities boosted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Stock Performance

NASDAQ PHVS traded down $0.54 during trading hours on Tuesday, hitting $15.96. The company had a trading volume of 29,290 shares, compared to its average volume of 70,665. Pharvaris has a 1-year low of $14.14 and a 1-year high of $26.57. The company has a market cap of $834.55 million, a PE ratio of -5.70 and a beta of -3.02. The business has a 50 day moving average of $17.10 and a 200-day moving average of $19.12.

Hedge Funds Weigh In On Pharvaris

Several large investors have recently bought and sold shares of PHVS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Pharvaris in the third quarter valued at $906,000. HighVista Strategies LLC boosted its stake in Pharvaris by 35.9% in the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock valued at $422,000 after acquiring an additional 6,018 shares in the last quarter. Patient Square Capital LP acquired a new position in Pharvaris in the third quarter valued at $4,488,000. State Street Corp acquired a new position in Pharvaris in the third quarter valued at $1,000,000. Finally, Sphera Funds Management LTD. raised its holdings in shares of Pharvaris by 8.9% in the third quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company’s stock valued at $8,136,000 after buying an additional 36,027 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.